Drug Pricing On The Right Side Of The Inflation Debate – At The Wrong Time
The US pharmaceutical industry is finally on the right side of the inflation debate, with drug price increases clearly lagging well behind overall consumer price growth. It is, however, probably too late to make a difference in the prospects of price control legislation.
You may also be interested in...
CBO highlights the pharma-friendly nature of Senate’s plan to limit patient cost-sharing for insulin. Meanwhile, White House urges Senate to pass Democrat’s more comprehensive and pharma-negative drug pricing bill instead of waiting for the revival of the Build Back Better deal.
US Senate’s updated version of drug pricing legislation is even worse for industry when it comes to the proposed price ‘negotiation’ authority, a Congressional Budget Office analysis indicates. The big numbers facing the industry just keep getting bigger.
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.